---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009607"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:12:51.564704+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix reports FY2022 revenue $6.1M, net loss $18.8M; cash $35.6M into Q2 2024

## Summary
- Revenue $6.1M (+$0.9M YoY); net loss $18.8M vs $20.2M; EPS -$5.46 vs -$8.63.
- Cash $35.6M at Dec 31, 2022; runway into Q2 2024.
- PUR1900 Phase 2b in ABPA dosed first patients in Q1 2023; topline data expected mid-2024.
- PUR3100 Phase 1 for acute migraine positive: lower nausea vs IV DHE; plans for Phase 2.
- PUR1800 Phase 1b data presented; analysis ongoing for potential Phase 2 study.

## SEC filing metadata
- accession: 0001493152-23-009607
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315223009607/0001493152-23-009607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315223009607/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009607
- JSON: https://secwatch.observer/filing/0001493152-23-009607.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009607.txt

## Key facts
- Earnings Releases
  Pulmatrix, Inc. reported the year ended December 31, 2022 results: revenue $6.1 million.
  - Period: the year ended December 31, 2022
  - Revenue: $6.1 million
  - Result: reported results
  source text: Revenue was $6.1 million for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574235/000149315223009607/0001493152-23-009607-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.